The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

All patients presented with rest pain requiring opiate management for more than 3 weeks, ulcers, or gangrene caused by peripheral arterial occlusive disease (Rutherford categories 4 and 5), [12 ...